Ochromycinone (STA 21) is a selective STAT3 inhibitor.

在细胞内，Ochromycinone抑制Stat3 DNA结合活性、Stat3二聚体形成以及Stat3依赖的荧光素酶活性。Ochromycinone显著抑制持续激活Stat3的乳腺癌细胞株MDA-MB-231、MDA-MB-435s和MDA-MB-468的生长与存活。[1] 在RH30和RD2细胞中，Ochromycinone同样通过caspases 3、8和9的途径抑制细胞活性与生长，并诱导凋亡。[2]

在IL-1Ra–KO小鼠中，STA-21（0.5 mg/kg，i.p.）通过降低Th17细胞比例并增加表达FoxP3的Treg细胞比例，从而降低关节炎评分和关节炎发病率。[3]

Human breast cancer cell lines MDA-MB-231, MDA-MB-435s, MDA-MB-453, MDA-MB-468, and MCF7, human ovarian carcinoma cell line Caov-3, and human skin fibroblasts were cultured in DMEM containing 10% FBS and appropriate antibiotics in a 5% CO2 incubator at 37°C. For testing different compounds, the cells were exposed to the compounds for 48 h at a final concentration of 20 or 30 μM, respectively. Then, the cells were harvested and subjected to flow-cytometry analysis.(Only for Reference)